The company's notable project includes the development of Avacincaptad Pegol, aimed at treating Geographic Atrophy secondary to AMD, a condition that leads to irreversible blindness. The acquisition combines IVERIC bio's expertise in ophthalmology with Astellas' global resources, enhancing their ability to develop and commercialize treatments for retinal diseases.
Cyborg Score Rationale
Pre-acquisition, IVERIC bio demonstrated strong IP and clinical progress in a high-need market. As an Astellas subsidiary since July 2023, it gains financial stability and global commercialization infrastructure, though public trading visibility has ceased. The $5.9B acquisition price reflects market confidence in geographic atrophy therapeutics.
Top Insights
Avacincaptad Pegol addresses geographic atrophy, a serious AMD complication with no current standard-of-care therapy, representing significant market opportunity.
Astellas acquisition (July 2023) removed public market risk and provided scale for manufacturing and global distribution in ophthalmology.
Gene therapy pipeline expansion pre-acquisition included programs for inherited retinal diseases (rhodopsin-mediated ADRP, BEST1-related, LCA10, Stargardt).
Company no longer trades publicly (delisted September 2023) but operates as integrated Astellas subsidiary focused on retinal disease therapeutics.
Named Competitors
Eylea — Leading anti-VEGF therapy for wet AMD and retinal diseases
Lucentis / Beovu — Anti-VEGF and beta-secretase inhibitor therapies for AMD
Vabysmo — Dual mechanism of action inhibitor for wet and dry AMD
Syfovre (pegcetacoplan) — FDA-approved complement C3 inhibitor for geographic atrophy in dry AMD
Fovista (anti-PlGF) — Anti-PlGF therapy in development for wet AMD
RGX-314 — Gene therapy for wet AMD expected to launch 2026
Recent Developments
(July 2023) Acquired by Astellas Pharma for $5.9 billion; stock delisted from NASDAQ
(November 2022) Completed $300 million public offering of common stock before acquisition
(October 2021) Raised $150.8 million through upsized public offering
Open the full interactive IVERIC bio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.